Trials / Withdrawn
WithdrawnNCT00830427
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
A Phase Iib Randomised Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of Pf-00610355 Over 4 Weeks In Moderate Asthmatic Subjects.
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a daily basis for 4 weeks in subjects maintained on inhaled corticosteroid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00610355 | 100 mcg, QD, dry powder inhaler |
| DRUG | PF - 00610355 | 600 mcg, QD, dry powder inhaler |
| OTHER | Placebo | QD, dry powder inhaler |
| DRUG | PF - 00610355 | 300 mcg, QD, dry powder inhaler |
Timeline
- Start date
- 2009-04-15
- Primary completion
- 2009-12-31
- Completion
- 2009-12-31
- First posted
- 2009-01-27
- Last updated
- 2019-01-31
Source: ClinicalTrials.gov record NCT00830427. Inclusion in this directory is not an endorsement.